BlueCrest Capital Management (UK)’s Biogen BIIB Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$223K	Buy	+674	New	+$222K	0.01%	474

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlueCrest Capital Management (UK)'s BIIB Position: Q3 2014 in Review

BlueCrest Capital Management (UK) opened a new position in Biogen (BIIB) in Q3 2014: 674 shares worth $223K. The stake represents 0.01% of the portfolio and ranks #474 among its holdings.

818 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

BlueCrest Capital Management (UK) held 674 shares of Biogen worth $223K as of Q3 2014.
Biogen was a new BlueCrest Capital Management (UK) position in Q3 2014.
Biogen made up 0.01% of BlueCrest Capital Management (UK)'s portfolio in Q3 2014, its #474 holding.
818 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.